{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:18Z","timestamp":1792785858962,"version":"4.5.0"},"reference-count":135,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australia CJ Martin Fellowship","award":["#1112125"],"award-info":[{"award-number":["#1112125"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1093\/cvr\/cvz022","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:32:01Z","timestamp":1548376321000},"page":"904-914","source":"Crossref","is-referenced-by-count":99,"title":["Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension"],"prefix":"10.1093","volume":"115","author":[{"given":"Jorie","family":"Versmissen","sequence":"first","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, CA Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M","family":"Mirabito Colafella","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, CA Rotterdam, The Netherlands"},{"name":"Cardiovascular Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia"},{"name":"Department of Physiology, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L W","family":"Koolen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"},{"name":"Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A H Jan","family":"Danser","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, CA Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B4","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.18632\/oncotarget.10019","article-title":"Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00228-013-1598-1","article-title":"Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis","volume":"70","author":"Wang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/jhh.2013.30","article-title":"Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis","volume":"27","author":"Funakoshi","year":"2013","journal-title":"J Hum Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","article-title":"Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase","volume":"46","author":"Sun","year":"2003","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-2125.2012.04417.x","article-title":"Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials","volume":"75","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40261-014-0174-5","article-title":"Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis","volume":"34","author":"Qi","year":"2014","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10637-017-0452-1","article-title":"Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis","volume":"35","author":"Roviello","year":"2017","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J Cardiol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/HJH.0b013e32835c1d1b","article-title":"Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1","volume":"31","author":"Lankhorst","year":"2013","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B16","doi-asserted-by":"crossref","DOI":"10.1242\/dev.151019","article-title":"Vascular endothelial growth factor signaling in development and disease","volume":"145","author":"Karaman","year":"2018","journal-title":"Development"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/pr.56.4.3","article-title":"Vascular endothelial growth factor and angiogenesis","volume":"56","author":"Hoeben","year":"2004","journal-title":"Pharmacol Rev"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling\u2014in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B19","doi-asserted-by":"crossref","first-page":"29120","DOI":"10.1074\/jbc.R115.687327","article-title":"Neuropilin functions as an essential cell surface receptor","volume":"290","author":"Guo","year":"2015","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B20","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.febslet.2013.05.038","article-title":"VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing","volume":"587","author":"Saito","year":"2013","journal-title":"FEBS Lett"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B21","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.117.09913","article-title":"Angiogenic markers predict pregnancy complications and prolongation in preeclampsia: continuous versus cutoff values","volume":"70","author":"Saleh","year":"2017","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B23","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cmet.2016.03.004","article-title":"VEGFB\/VEGFR1-induced expansion of adipose vasculature counteracts obesity and related metabolic complications","volume":"23","author":"Robciuc","year":"2016","journal-title":"Cell Metab"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nm.1960","article-title":"Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism","volume":"15","author":"Machnik","year":"2009","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B26","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1084\/jem.20062642","article-title":"Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting","volume":"204","author":"Wirzenius","year":"2007","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B27","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/MCB.25.6.2441-2449.2005","article-title":"Vascular endothelial growth factor D is dispensable for development of the lymphatic system","volume":"25","author":"Baldwin","year":"2005","journal-title":"Mol Cell Biol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B28","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B30","doi-asserted-by":"crossref","first-page":"17009.","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B32","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clon.2017.02.009","article-title":"Targeted therapy in thyroid cancer: state of the art","volume":"29","author":"Valerio","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/SLA.0b013e31815fa447","article-title":"Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma","volume":"247","author":"Yu","year":"2008","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejso.2010.10.010","article-title":"Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes","volume":"37","author":"Salajegheh","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B38","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B41","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","article-title":"Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a Multicenter Phase II International Thyroid Oncology Group trial","volume":"35","author":"Cabanillas","year":"2017","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B42","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","article-title":"HGF\/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors","volume":"70","author":"Shojaei","year":"2010","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B43","doi-asserted-by":"crossref","first-page":"75478","DOI":"10.18632\/oncotarget.20796","article-title":"Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B46","doi-asserted-by":"crossref","first-page":"17.","DOI":"10.1186\/s40164-018-0109-6","article-title":"Emerging therapies in advanced hepatocellular carcinoma","volume":"7","author":"Medavaram","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B48","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1158\/1078-0432.CCR-07-0895","article-title":"Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate","volume":"13","author":"McAuliffe","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2017.09.025","article-title":"Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib","volume":"86","author":"Verboom","year":"2017","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B50","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B52","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11040","article-title":"Cardiac angiogenic imbalance leads to peripartum cardiomyopathy","volume":"485","author":"Patten","year":"2012","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B54","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B55","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/HYPERTENSIONAHA.117.09275","article-title":"Hypertension and VEGF (Vascular Endothelial Growth Factor) receptor tyrosine kinase inhibition: effects on renal function","volume":"70","author":"Boursiquot","year":"2017","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B56","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2016.147","article-title":"Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data","volume":"114","author":"Sorich","year":"2016","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B57","doi-asserted-by":"crossref","first-page":"22332","DOI":"10.18632\/oncotarget.24900","article-title":"Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer","volume":"9","author":"Roviello","year":"2018","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B58","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bph.14103","article-title":"Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension","volume":"175","author":"Collins","year":"2018","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B59","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrclinonc.2014.40","article-title":"Determining the optimal dose in the development of anticancer agents","volume":"11","author":"Mathijssen","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B61","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.115.05435","article-title":"Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib","volume":"66","author":"Lankhorst","year":"2015","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B63","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FJC.0b013e3181993493","article-title":"ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats","volume":"53","author":"Banfor","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bcp.2012.03.020","article-title":"Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease","volume":"84","author":"Mazzuca","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B66","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1753944715624853","article-title":"The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia","volume":"10","author":"Saleh","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B67","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B68","doi-asserted-by":"crossref","first-page":"e91897.","DOI":"10.1371\/journal.pone.0091897","article-title":"SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice","volume":"9","author":"Amraoui","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B69","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.111.00841","article-title":"Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans","volume":"61","author":"Thijs","year":"2013","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B70","first-page":"503","article-title":"Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B72","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/HYPERTENSIONAHA.117.10225","article-title":"Pazopanib-induced hypertension in patients with renal cell carcinoma is associated with low urine excretion of NO metabolites","volume":"71","author":"Tinning","year":"2018","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B74","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B75","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.110.168120","article-title":"Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans","volume":"58","author":"Mayer","year":"2011","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/01.HYP.0000138070.47616.9d","article-title":"Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?","volume":"44","author":"Touyz","year":"2004","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B77","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.2174\/1381612821666151029111127","article-title":"Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase","volume":"21","author":"Chan","year":"2015","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B78","doi-asserted-by":"crossref","first-page":"3203.","DOI":"10.1242\/jcs.195966","article-title":"Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration","volume":"129","author":"El-Remessy","year":"2016","journal-title":"J Cell Sci"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B79","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12192-012-0331-9","article-title":"Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity","volume":"17","author":"Mohammadzadeh","year":"2012","journal-title":"Cell Stress Chaperones"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B80","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.3748\/wjg.v19.i28.4464","article-title":"Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy","volume":"19","author":"Marques","year":"2013","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B81","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (Vascular Endothelial Growth Factor Receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B82","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/CIRCRESAHA.112.267054","article-title":"Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase","volume":"110","author":"Schroder","year":"2012","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/ars.2013.5302","article-title":"Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research","volume":"20","author":"Montezano","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B84","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B85","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B86","doi-asserted-by":"crossref","first-page":"e11.","DOI":"10.1016\/j.clinthera.2014.05.055","article-title":"Early rise in aldosteron is correlated with increase in blood pressure in sunitinib treated patients with metastatic renal cell carcinoma","volume":"36","author":"Thijs","year":"2014","journal-title":"Clin Ther (Abstract)"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B87","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.118.10854","article-title":"Renin-angiotensin-aldosterone profiles in pregnant women with chronic hypertension","volume":"72","author":"Malha","year":"2018","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1042\/cs0450115","article-title":"Plasma renin activity, plasma angiotensin and plasma and urinary electrolytes in normal and toxaemic pregnancy, including a prospective study","volume":"45","author":"Gordon","year":"1973","journal-title":"Clin Sci"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B89","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/HYPERTENSIONAHA.115.05267","article-title":"Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression","volume":"65","author":"Verdonk","year":"2015","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B90","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.29972","article-title":"Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: a pooled secondary analysis of clinical trials","volume":"138","author":"Sorich","year":"2016","journal-title":"Int J Cancer"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B91","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clgc.2016.10.004","article-title":"Therapy of treatment-related hypertension in metastatic renal-cell cancer patients receiving sunitinib","volume":"15","author":"Ivanyi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B92","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/HYPERTENSIONAHA.111.00575","article-title":"Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia","volume":"61","author":"Gennari-Moser","year":"2013","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B93","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/HJH.0000000000001894","article-title":"Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy","volume":"36","author":"Versmissen","year":"2018","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B95","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ndt\/gfv410","article-title":"Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib","volume":"31","author":"Lankhorst","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B96","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.116.08565","article-title":"Salt sensitivity of angiogenesis inhibition-induced blood pressure rise: role of interstitial sodium accumulation?","volume":"69","author":"Lankhorst","year":"2017","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B97","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/HYPERTENSIONAHA.117.10003","article-title":"Novel mechanism for buffering dietary salt in humans: effects of salt loading on skin sodium, vascular endothelial growth factor C, and blood pressure","volume":"70","author":"Selvarajah","year":"2017","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B98","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/HYPERTENSIONAHA.112.198879","article-title":"Urinary plasmin activates collecting duct ENaC current in preeclampsia","volume":"60","author":"Buhl","year":"2012","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B99","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00424-014-1661-5","article-title":"Urinary serine proteases and activation of ENaC in kidney\u2014implications for physiological renal salt handling and hypertensive disorders with albuminuria","volume":"467","author":"Svenningsen","year":"2015","journal-title":"Pflugers Arch"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1172\/JCI0213229","article-title":"Regulation of prostasin by aldosterone in the kidney","volume":"109","author":"Narikiyo","year":"2002","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B101","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2215\/CJN.12261115","article-title":"Association of plasminuria with overhydration in patients with CKD","volume":"11","author":"Schork","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B102","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1056\/NEJM199809033391004","article-title":"Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units","volume":"339","author":"Sibai","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.preghy.2015.08.001","article-title":"Microalbuminuria is a predictor of adverse pregnancy outcomes including preeclampsia","volume":"5","author":"Jayaballa","year":"2015","journal-title":"Pregnancy Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B104","doi-asserted-by":"crossref","first-page":"e0204514.","DOI":"10.1371\/journal.pone.0204514","article-title":"Pre-eclampsia is associated with altered expression of the renal sodium transporters NKCC2, NCC and ENaC in urinary extracellular vesicles","volume":"13","author":"Hu","year":"2018","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B105","doi-asserted-by":"crossref","first-page":"R1326","DOI":"10.1152\/ajpregu.00082.2010","article-title":"Increased renal alpha-epithelial sodium channel (ENAC) protein and increased ENAC activity in normal pregnancy","volume":"299","author":"West","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol Rev"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B107","doi-asserted-by":"crossref","first-page":"F1063","DOI":"10.1152\/ajprenal.90321.2008","article-title":"Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct","volume":"295","author":"Bugaj","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B108","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/bs.vh.2015.01.001","article-title":"Inhibition of ENaC by endothelin-1","volume":"98","author":"Sorokin","year":"2015","journal-title":"Vitam Horm"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B109","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B110","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B112","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1042\/CS20171366","article-title":"Endothelin type B (ETB) receptors: friend or foe in the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk?","volume":"132","author":"Mirabito Colafella","year":"2018","journal-title":"Clin Sci"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B114","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10456-012-9327-4","article-title":"Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension","volume":"16","author":"Kruzliak","year":"2013","journal-title":"Angiogenesis"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ajh\/hpt201","article-title":"Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors","volume":"27","author":"Kruzliak","year":"2014","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B116","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.redox.2015.09.007","article-title":"Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors","volume":"6","author":"Leon-Mateos","year":"2015","journal-title":"Redox Biol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B117","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1203275109","article-title":"Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition","volume":"109","author":"Sunshine","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B118","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000343414","article-title":"Renoprotective effects of sildenafil in DOCA-salt hypertensive rats","volume":"36","author":"Bae","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B119","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1476-5381.2010.01149.x","article-title":"Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats","volume":"162","author":"Kuno","year":"2011","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B120","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1681\/ASN.2015080885","article-title":"Sildenafil prevents podocyte injury via PPAR-gamma-mediated TRPC6 inhibition","volume":"28","author":"Sonneveld","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B121","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1681\/ASN.2006091010","article-title":"Induction of TRPC6 channel in acquired forms of proteinuric kidney disease","volume":"18","author":"Moller","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B122","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3892\/ijo.2017.3936","article-title":"Inflammatory role of high salt level in tumor microenvironment (Review)","volume":"50","author":"Amara","year":"2017","journal-title":"Int J Oncol"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B123","first-page":"CD005548","article-title":"Altered dietary salt for preventing pre-eclampsia, and its complications","volume":"4","author":"Duley","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B124","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/HJH.0000000000001650","article-title":"The role of distal tubule and collecting duct sodium reabsorption in sunitinib-induced hypertension","volume":"36","author":"Witte","year":"2018","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B125","doi-asserted-by":"crossref","first-page":"e13743.","DOI":"10.14814\/phy2.13743","article-title":"Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report","volume":"6","author":"Hinrichs","year":"2018","journal-title":"Physiol Rep"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B126","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B127","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B128","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B129","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","article-title":"Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies","volume":"369","author":"Flossmann","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B130","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.18632\/oncotarget.3437","article-title":"Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs","volume":"6","author":"Ben-Batalla","year":"2015","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B131","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B132","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B133","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000320609","article-title":"Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer","volume":"79","author":"Manzoni","year":"2010","journal-title":"Oncology"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B134","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","article-title":"Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma","volume":"70","author":"Atkins","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t2019040805030129000_cvz022-B135","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/115\/5\/904\/28283252\/cvz022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T17:23:48Z","timestamp":1606152228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/115\/5\/904\/5304413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":135,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,6]]},"published-print":{"date-parts":[[2019,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvz022","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,15]]},"published":{"date-parts":[[2019,2,6]]}}}